Skip to main content

Table 3 TNF-α and IL-10 production in LPS challenged PBMCs incubated with oligosaccharide fractions

From: In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation

 

TNF- α (pg/ml)

  

IL-10 (pg/ml)

  

Incubation

Point estimate

Lower bound

Upper bound

Point estimate

Lower bound

Upper bound

LPS 1 μg/ml

1749.4

1495.2

2050.8

278.1

236.0

328.7

LPS + GOS 0.5%

3655.5 *

3115.0

4285.5

293.8

248.4

347.6

LPS + GOS 1.0%

4989.0 * #

4251.4

5843.0

268.8

227.5

316.7

LPS + GOS 2.0%

7754.3 * #

6607.8

9090.6

265.6

225.0

313.6

LPS + GOS/FOS 0.5%

3601.1 *

3074.8

4221.7

344.1

290.9

407.5

LPS + GOS/FOS 1.0%

5530.3 * #

4712.6

6483.4

307.4

260.6

362.9

LPS + GOS/FOS 2.0%

6721.1 *

5733.0

7879.3

264.0

223.9

311.7

LPS + GOS/FOS/AOS 0.5%

4242.9 *

3608.3

4969.1

374.3 *

317.0

442.3

LPS + GOS/FOS/AOS 1.0%

3317.6 * #

2832.7

3893.3

269.6 #

227.9

318.3

LPS + GOS/FOS/AOS 2.0%

1029.7 * #

874.8

1205.9

180.7 * #

149.0

216.6

  1. Mean protein concentrations of TNF-α and IL-10 (pg/ml) and 95% Bayesian Credible Intervals for LPS challenged PBMCs incubated with oligosaccharide fractions (including incubations with LPS alone). Significant differences between oligosaccharide fractions and LPS alone are marked with an asterisk (*). Significant dose-dependent differences (1.0% vs. 0.5% and 2.0% vs. 1.0%) are marked with a hash (#).